Neurological disease remains a leading cause of illness and disability worldwide. In the United States alone, the annual economic burden of Alzheimer’s disease and related dementias is now estimated at $780 billion and rising as the baby-boomer generation ages. Yet, more than nine in ten cases of mild cognitive impairment go undiagnosed and over 20 states have so-few dementia specialists that public health experts are warning of emerging “dementia neurology deserts.”
The consequences are stark: patients miss the window to benefit from disease-modifying therapies and clinical-trial enrollment, and caregivers in turn are shouldering an unsustainable load. As providers and payers seek to better manage these patients, powerful tailwinds are emerging to reduce this burden (GUIDE, HCC V28) – yet critical gaps persist. The combination of these clinical, financing, and pharmaceutical dynamics has created an opening for a neurologist‑led virtual neurology platform to expand access to timely diagnosis and evidence-based, guideline-level treatment that links patients to research.
Today, Flare Capital Partners is thrilled to lead Isaac Health’s $10.5 million Series A as the company develops a category-leading, end-to-end virtual neurology platform. We are excited to be joined by investors Meridian Street Capital, B Capital, Industry Ventures, Primetime Partners, and Black Opal Ventures.
The team boasts robust scientific depth with clinical and operational expertise from institutions including the University of Cambridge, NYU Langone Health, McKinsey & Company, and Mass General Brigham. Co-Founder and CEO Dr. Julius Bruch, MD, PhD, earned his doctorate in neurodegeneration and is a Cambridge-trained physician. CMO Dr. Joel Salinas, MD, MBA, MSc, FAAN, is a behavioral neurologist at NYU Langone Health’s Memory Center, a renowned clinician-scientist, former Clinical Director at Mass General’s McCance Center for Brain Health, and a revered author who has contributed to eight books on neurology.
Market Opportunity
Isaac Health is capitalizing on powerful tailwinds that make this the right moment to build a category-defining virtual neurology platform. Policy momentum continues to push the industry toward cost-efficient care: CMS has introduced the eight-year GUIDE dementia model, and HCC V28 now rewards payers and risk-bearing providers that proactively diagnose and manage cognitive impairment.
Therapeutic breakthroughs continue to advance. A new class of anti-amyloid therapies (AATs) mark a scientific milestone, with technologies on the horizon (e.g., Brainshuttle by Roche) that show promise. This wave of therapeutic intervention coincides with a >$60 billion pipeline of global neurodegenerative drug candidates that depend on timely, accurate diagnosis.
Isaac Health’s Evidence-Based Care Model
Isaac Health’s breakthrough lies in its cutting-edge approach to care delivery which combines human expertise with AI-powered diagnostics and workflows, pioneering an industry-leading clinical model inspired by evidence-based models developed at institutions like UCLA and UCSF. Isaac Health tackles core gaps in traditional neurology care via a neurologist-led model that spans the full continuum of care. The company starts with AI-powered identification of at-risk members, then delivers longitudinal disease management and caregiver support.
Proprietary screening algorithms surface high-risk individuals across claims and EHR datasets and drive evidence-based diagnostic pathways. Caregiver-centric support is delivered virtually and, when needed, through in-home partners. Isaac Health is now licensed in 50 states and covers 400,000+ Medicare lives and 20,000+ Medicaid lives, with over 5,000 members screened via their proprietary screening tool. Isaac Health’s flexible “plug-and-play” model for care lets health plans and risk-bearing provider groups choose the mix of virtual and in-person services that best fits their needs. Robust evaluations of Isaac Health’s enrolled patients confirm improvements in cognitive skills, higher engagement, and significant medical cost savings – helping health plans achieve a greater than 4:1 ROI.
Isaac Health demonstrated clinical efficacy and financial efficiency in a matched case-control study independently validated by the Validation Institute. Nearly 73% of managed patients showed improved neurocognitive function after six months, and 92% met cognitive goals. The platform can also deliver meaningful cost reductions, fewer ED visits, and shorter hospital stays while boosting Medicare Advantage (MA) revenue by closing dementia-related coding gaps. Commercial traction is strong: Isaac Health has partnered with national and regional health plans, risk-bearing MSOs and medical groups, and multiple pharmacy home-management vendors.
Further, Isaac Health is the first virtual provider delivering safe, active treatment of AAT, which serves as a differentiator for the platform that will service the life sciences sector long-term. A testament to the Isaac Health care team.
The Leadership Behind It All
Great companies are built by great people. Co-founder & CEO Dr. Julius Bruch, MD, PhD, is a Cambridge-trained clinician-scientist with a doctorate in neurodegeneration and seven years at McKinsey advising global healthcare organizations. Co-founder and CMO Dr. Joel Salinas, MD, MBA, MSc, FAAN, is a nationally recognized behavioral neurologist at NYU Langone Health’s Memory Center and the former clinical director at Mass General’s McCance Center for Brain Health. Julius and Joel have assembled a purpose-built team of operators and engineers, whose experience spans Kyruus Health, Mass General Brigham, IBM, Harvard, and more – a rare blend of scientific depth and execution prowess.
Our team has known Julius and Joel since their earliest prototyping days and has watched them translate vision into a highly capital-efficient business that aligns perfectly with our thesis of enabling value through next-generation specialty care.
Looking Forward
As more partners and patients come onboard, we expect Isaac Health to continue driving strong ROI (>4:1) via disease-modifying therapies and patient-centered care. Longer-term, Isaac Health’s future roadmap goes well beyond dementia. The same clinical engine can address adjacent neurological conditions, power real-world-evidence (RWE) collaborations with pharmaceutical companies and helping health plans and risk-bearing providers to thrive in value-based arrangements.
We’re excited to partner with Isaac Health’s leadership and support their growth as they build the trusted, category-defining virtual neurology clinic.
To learn more about Isaac Health: reach out to Ian Chiang (ian@www.flarecapital.com), Jon George (jon@www.flarecapital.com), or any member of the Flare Capital team – we would love to hear from you.
Careers: Isaac Health is hiring across clinical, engineering, and operations roles. Explore open positions here.
Stay in touch with Flare Capital:
Axios coverage here: https://www.axios.com/pro/health-tech-deals/2025/08/14/isaac-health-dementia-care-series-a
